TNF-α: An activator of CD4+FoxP3+TNFR2+regulatory T cells

TNF Pathophysiology: Molecular and Cellular Mechanisms

Volumn 11, Issue , 2010, Pages 119-134

  Chen, Xin ^a   Oppenheim, Joost J ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926109500     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000289201     Document Type: Chapter

References (90)

1. Gershon RK, Kondo K: Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970;18:723-737.
2. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
3. Sakaguchi S, Yamaguchi T, Nomura T, Ono M:Regulatory T cells and immune tolerance. Cell 2008; 133:775-787.
4. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886.
5. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY: An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat Immunol 2006;7:401-410.
6. Zheng Y, Rudensky AY: Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007;8:457-462.
7. Torgerson TR, Ochs HD: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007;120:744-750; quiz 751-742.
8. Campbell DJ, Ziegler SF: FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 2007;7:305-310.
9. Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
10. Piccirillo CA, Shevach EM: Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-1140.
11. Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A: CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004;112:258-267.
12. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H: Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003;63:4516-4520.
13. Cederbom L, Hall H, Ivars F: CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000;30:1538-1543.
14. Fu Y, Yi S, Wu J, Jimenez E, Simond D, Hawthorne WJ, O'Connell PJ: In vitro suppression of xenoimmune-mediated macrophage activation by human CD4+CD25+ regulatory T cells. Transplantation 2008;86:865-874.
15. Seo SJ, Fields ML, Buckler JL, Reed AJ, Mandik-Nayak L, Nish SA, Noelle RJ, Turka LA, Finkelman FD, Caton AJ, Erikson J: The impact of T helper and T regulatory cells on the regulation of anti-doublestranded DNA B cells. Immunity 2002;16:535-546.
16. Thornton AM, Shevach EM: Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164:183-190.
17. Karim M, Feng G, Wood KJ, Bushell AR:CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005;105:4871-4877.
18. Belkaid Y, Rouse BT: Natural regulatory T cells in infectious disease. Nat Immunol 2005;6:353-360.
19. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
20. Miyara M, Sakaguchi S: Natural regulatory T cells:mechanisms of suppression. Trends Mol Med 2007; 13:108-116.
21. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-569.
22. Allan SE, Song-Zhao GX, Abraham T, McMurchy AN, Levings MK: Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol 2008;38:3282-3289.
23. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Hermine A, Devergne O: Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008;181:6898-6905.
24. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC: Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-1265.
25. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S:CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271-275.
26. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M, Der SD, Kang J, Chambers CA: CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009;206:421-434.
27. Aggarwal BB: Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-756.
28. Cope AP: Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998;10:669-676.
29. Clark J, Vagenas P, Panesar M, Cope AP: What does tumour necrosis factor excess do to the immune system long term? Ann Rheum Dis 2005; 64(suppl 4):iv70-iv76.
30. Kollias G, Kontoyiannis D: Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002;13:315-321.
31. Kruglov AA, Kuchmiy A, Grivennikov SI, Tumanov AV, Kuprash DV, Nedospasov SA: Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade:mouse models. Cytokine Growth Factor Rev 2008;19:231-244.
32. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA: Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996;184:1963-1974.
33. Jacob CO, McDevitt HO: Tumour necrosis factoralpha in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-358.
34. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H: Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci USA 1990;87:968-972.
35. Kontoyiannis D, Kollias G: Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000;30:2038-2047.
36. Kollias G, Kontoyiannis D, Douni E, Kassiotis G:The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized 'anti-TNF' therapies. Curr Dir Autoimmun 2002;5:30-50.
37. Kassiotis G, Kollias G: Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001; 193:427-434.
38. Valencia X, Lipsky PE: CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 2007;3:619-626.
39. Leipe J, Skapenko A, Lipsky PE, Schulze-Koops H:Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 2005;7:93.
40. Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C: Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003;33:215-223.
41. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS: CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004;50:2775-2785.
42. Mottonen M, Heikkinen J, Mustonen L, Isomaki P, Luukkainen R, Lassila O: CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005;140:360-367.
43. Jiao Z, Wang W, Jia R, Li J, You H, Chen L, Wang Y:Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol 2007;36:428-433.
44. Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, Sallusto F: Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005;201:1793-1803.
45. de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, de Jager W, Pugayung G, Giannoni F, Rijkers G, Albani S, Kuis W, Prakken B:CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004;172:6435-6443.
46. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V: CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004; 6:R335-R346.
47. Nguyen LT, Jacobs J, Mathis D, Benoist C: Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum 2007;56:509-520.
48. Monte K, Wilson C, Shih FF: Increased number and function of FoxP3 regulatory T cells during experimental arthritis. Arthritis Rheum 2008;58:3730-3741.
49. Venet F, Chung CS, Monneret G, Huang X, Horner B, Garber M, Ayala A: Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2008;83:523-535.
50. Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ: Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 2007;179:154-161.
51. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860-867.
52. Wu AJ, Hua H, Munson SH, McDevitt HO: Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 2002;99:12287-12292.
53. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM: Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3+CD4+ CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006; 36:2139-2149.
54. Chen X, Winkler-Pickett RT, Carbonetti NH, Ortaldo JR, Oppenheim JJ, Howard OM: Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol 2006;36:671-680.
55. Cassan C, Piaggio E, Zappulla JP, Mars LT, Couturier N, Bucciarelli F, Desbois S, Bauer J, Gonzalez-Dunia D, Liblau RS: Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. J Immunol 2006; 177:1552-1560.
56. Tonon S, Goriely S, Aksoy E, Pradier O, Del Giudice G, Trannoy E, Willems F, Goldman M, De Wit D:Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns. Eur J Immunol 2002;32:3118-3125.
57. Ausiello CM, Fedele G, Urbani F, Lande R, Di Carlo B, Cassone A: Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J Infect Dis 2002;186:351-360.
58. Chen X, Howard OM, Oppenheim JJ: Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J Immunol 2007;178:6123-6129.
59. Malek TR, Bayer AL: Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004;4:665-674.
60. Carpentier I, Coornaert B, Beyaert R: Function and regulation of tumor necrosis factor type 2. Curr Med Chem 2004;11:2205-2212.
61. Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM, Palladino MA Jr: Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 1993;151:4637-4641.
62. Kim EY, Priatel JJ, Teh SJ, Teh HS: TNF receptor type 2 (p75) functions as a costimulator for antigendriven t cell responses in vivo. J Immunol 2006;176:1026-1035.
63. Kim EY, Teh HS: TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 2001; 167:6812-6820.
64. Kim EY, Teh HS: Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol 2004;173:4500-4509.
65. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S:Phenotype, localization, and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 2002;196:379-387.
66. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S, Annunziato F: Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003;102:4107-4114.
67. Chen X, Subleski JJ, Kopf H, Howard OM, Mannel DN, Oppenheim JJ: Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells:applicability to tumor-infiltrating T regulatory cells. J Immunol 2008;180:6467-6471.
68. Baseta JG, Stutman O: TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset. J Immunol 2000;165:5621-5630.
69. van Mierlo GJ, Scherer HU, Hameetman M, Morgan ME, Flierman R, Huizinga TW, Toes RE: Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J Immunol 2008;180:2747-2751.
70. Kollias G: TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 2005;34:3-6.
71. Suvannavejh GC, Lee HO, Padilla J, Dal Canto MC, Barrett TA, Miller SD: Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 2000;205:24-33.
72. Ebach DR, Riehl TE, Stenson WF: Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture. Shock 2005;23:311-318.
73. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
74. Lehmann J, Huehn J, de la Rosa M, Maszyna F, Kretschmer U, Krenn V, Brunner M, Scheffold A, Hamann A: Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25-regulatory T cells. Proc Natl Acad Sci USA 2002; 99:13031-13036.
75. Gray JD, Liu T, Huynh N, Horwitz DA: Transforming growth factor beta enhances the expression of CD154 (CD40L) and production of tumor necrosis factor alpha by human T lymphocytes. Immunol Lett 2001;78:83-88.
76. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA:Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 2009;58:1219-1228.
77. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277-285.
78. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE: TNF downmodulates the function of human CD4+CD25hi T regulatory cells. Blood 2006;108:253-261.
79. Feldmann M: Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-371.
80. Toubi E, Kessel A, Mahmudov Z, Hallas K, Rozenbaum M, Rosner I: Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 2005;1051:506-514.
81. Nadkarni S, Mauri C, Ehrenstein MR: Anti-TNFalpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-39.
82. Deepe GS Jr, Gibbons RS: TNF-alpha antagonism generates a population of antigen-specific CD4+ CD25+ T cells that inhibit protective immunity in murine histoplasmosis. J Immunol 2008;180:1088-1097.
83. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO: Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008;205:2491-2497.
84. Zakharova M, Ziegler HK: Paradoxical anti-inflammatory actions of TNF-alpha: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J Immunol 2005;175:5024-5033.
85. Ma X, Sun J, Papasavvas E, Riemann H, Robertson S, Marshall J, Bailer RT, Moore A, Donnelly RP, Trinchieri G, Montaner LJ: Inhibition of IL-12 production in human monocyte-derived macrophages by TNF. J Immunol 2000;164:1722-1729.
86. McTiernan CF, Mathier MA, Zhu X, Xiao X, Klein E, Swan CH, Mehdi H, Gibson G, Trichel AM, Glorioso JC, Feldman AM, McCurry KR, London B: Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther 2007;14:1613-1622.
87. Hajjar RJ, Zsebo K: AAV vectors and cardiovascular disease: targeting TNF receptor in the heart: clue to way forward with AAV? Gene Ther 2007;14:1611-1612.
88. Mostbock S: Cytokine/antibody complexes: an emerging class of immunostimulants. Curr Pharm Des 2009;15:809-825.
89. Wilson MS, Pesce JT, Ramalingam TR, Thompson RW, Cheever A, Wynn TA: Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol 2008;181:6942-6954.
90. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO: Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-1584.